Currently, the wording of the indication in section 4.1 of the SmPC (Summary of Product Characteristics) for recently approved centrally authorised medicinal products intended for the treatment of patients with type 2 diabetes contains 2 sections addressing mono- and combination therapy,[…] One of the reasons to specifically describe monotherapy in the indication wording is to reflect the widely accepted recommendation to use metformin as first line treatment.